Unilabs inks deal to sell C2N Alzheimer’s blood tests in Europe

MedTech Dive August 12, 2024
Nick Paul Taylor

C2N Diagnostics announced the partnership after recently receiving an investment from the Japanese drugmaker Eisai, which developed the Alzheimer’s drug Leqembi with Biogen.

Dive Brief:

• Unilabs has struck a deal to distribute C2N Diagnostics’ Alzheimer’s disease blood tests in Europe and certain other regions, the companies said last week.
• C2N has developed blood tests for detecting amyloid plaques and neurofibrillary “tau” tangles, which the company said are “pathological hallmarks of Alzheimer’s disease.” The tests provide a non-invasive way to evaluate markers of mild cognitive impairment and dementia.
• The PrecivityAD amyloid plaque test received a CE mark in 2020. Unilabs expects to make C2N tests available to its customers in the coming months.

Dive Insight:

Amyloid PET scans and...

Today's Sponsors

Today's Sponsor